Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03378635 · ClinicalTrials.gov registry record · Phase 3
A Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Type 1 Diabetes Subjects
A Phase 3 study, sponsored by Zealand Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 170
- Enrollment target
NCT03378635 is a Phase 3 study that has completed, run by Zealand Pharma. The registered enrollment target is 170 participants.
The verdict
NCT03378635, a Phase 3 study, has completed, sponsored by Zealand Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 170 participants
- Enrollment target
Study Summary
The objective of the trial is to demonstrate superiority of dasiglucagon compared to placebo following a single subcutaneous dose administered to subjects with type 1 diabetes mellitus (T1DM) with insulin-induced hypoglycemia. Additionally to compare the glycemic response observed after administration dasiglucagon with that of GlucaGen®.
Interventions
- DRUG Placebo
- DRUG GlucaGen
- DRUG Dasiglucagon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2017-12-07 |
| Est. Completion | 2018-05-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03378635
The ClinicalTrials.gov registry entry for NCT03378635 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 170 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Zealand Pharma, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03378635 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03378635 about?
NCT03378635 is a clinical study titled "A Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Type 1 Diabetes Subjects". The objective of the trial is to demonstrate superiority of dasiglucagon compared to placebo following a single subcutaneous dose administered to subjects with type 1 diabetes mellitus (T1DM) with insulin-induced hypoglycemia. Additionally to compare the glycemic response observed after administrati...
What is the current status of trial NCT03378635?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 170 participants. The study started on 2017-12-07. Estimated completion is 2018-05-25.
What interventions are being tested in trial NCT03378635?
The interventions under investigation include: Placebo (DRUG), GlucaGen (DRUG), Dasiglucagon (DRUG).
Who is sponsoring clinical trial NCT03378635?
This trial is sponsored by Zealand Pharma, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.